MedPath

Population-based Study in Screening for Liver Fibrosis

Completed
Conditions
Liver Diseases
Registration Number
NCT03789825
Lead Sponsor
Judit Pich Martínez
Brief Summary

Study to assess the prevalence of significant liver fibrosis in general population using Transient Elastography

Detailed Description

This is a population-based study. Subjects will attend a primary care center where a physical examination, general blood test and transient elastography will be carried out. Only the group of patients with high-risk for liver fibrosis will be evaluated in a second visit at the University Hospital.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
30000
Inclusion Criteria
  • Age ≥ 40 years
  • Able to give informed consent
Exclusion Criteria
  • Previously known chronic liver disease (including cholestasis). Patients with already known liver steatosis but no diagnosis of liver fibrosis or cirrhosis can be included
  • Subjects with mental incapacity, language barrier, insufficient social support or any other reason considered by the investigator precluding adequate understanding or cooperation in the study
  • Subjects with a history of current malignancy including solid tumors and hematologic disorders
  • Subjects with significant extrahepatic disease that may impair short-term prognosis (including congestive heart failure New York Heart Association Grade IV, COPD GOLD >3)
  • Subjects with kidney disease (serum creatinine >3mg/dL or under renal replacement therapy)

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
% of subjects with Liver stiffness measurement by Transient Elastography >=8 kPa at any visitThrough study completion, an average of 24 months

Percentage of subjects with Liver stiffness measurement by Transient Elastography ≥ 8 kPa at any visit, either with M or XL probe, in general population.

Secondary Outcome Measures
NameTimeMethod
% of subjects with Liver stiffness measurement by Transient Elastography >=8 kPa in the subgroup of patients with risk factors for chronic liver disease at visit 1 or 2Through study completion, an average of 24 months

Percentage of subjects with Liver stiffness measurement by Transient Elastography ≥ 8 kPa, either with M or XL probe, in the subgroup of patients with risk factors for chronic liver disease at visit 1 and/or 2.

Comparison of liver fibrosis diagnosis accuracy between Transient Elastography and fibrosis scoresThrough study completion, an average of 24 months

Comparison of liver fibrosis diagnosis accuracy between Transient Elastography and fibrosis scores (including NAFLD fibrosis score, FIB-4, Forms index and APRI score) for the diagnosis of liver fibrosis in general population and in the subgroup of patients with risk factors for chronic liver disease at visit 1 and 2.

Comparison of liver fibrosis diagnosis accuracy between Transient Elastography, fibrosis scores and liver biopsyThrough study completion, an average of 24 months

Comparison of liver fibrosis diagnosis accuracy between Transient Elastography, fibrosis scores and liver biopsy for the diagnosis of liver fibrosis in general population and in the subgroup of patients with risk factors for chronic liver disease, in patients with liver biopsy available at visit 2.

% of subjects with CAP ≥250 dB/mThrough study completion, an average of 24 months

Percentage of subjects with CAP ≥250 dB/m, either with M or XL probe, in general population and in the subgroup of patients with risk factors for chronic liver disease at visit 1 and/or 2

Comparison of liver steatosis diagnosis accuracy between CAP and steatosis scoresThrough study completion, an average of 24 months

Comparison of liver steatosis diagnosis accuracy between CAP and steatosis scores (including FLI, HIS, LAP, ION and NAFLD-LFS) for the diagnosis of liver steatosis in general population and in the subgroup of patients with risk factors for chronic liver disease at visit 1 and 2.

Comparison of liver steatosis diagnosis accuracy between CAP, steatosis scores and liver biopsyThrough study completion, an average of 24 months

Comparison of liver steatosis diagnosis accuracy between CAP, steatosis scores (including FLI, HIS, LAP, ION and NAFLD-LFS) and liver biopsy for the diagnosis of liver steatosis in general population and in the subgroup of patients with risk factors for chronic liver disease, in patients with liver biopsy available (at visit 2).

Comparison of liver steatosis diagnosis accuracy between CAP and abdominal ultrasoundThrough study completion, an average of 24 months

Comparison of liver steatosis diagnosis accuracy between CAP and abdominal ultrasound for the diagnosis of liver steatosis in general population and in the subgroup of patients with risk factors for chronic liver disease, in patients with abdominal ultrasound available at visit 2.

Comparison of values obtained with M and XL probes in the assessment of LSM and CAP via TEThrough study completion, an average of 24 months

Comparison of values obtained with M and XL probes in the assessment of LSM and CAP via TE at visit 2.

Cost-effectiveness of a liver fibrosis screening program for liver fibrosis detection in general populationThrough study completion, an average of 24 months

Cost-effectiveness of a liver fibrosis screening program for liver fibrosis detection in general population and in the subgroup of patients with risk factors for chronic liver disease. Direct and indirect cost savings of early detection of liver fibrosis in subjects with risk factors for chronic liver diseases.

Percentage of failure rate for stiffness and steatosis measurements within TE examinationThrough study completion, an average of 24 months

Percentage of failure rate for stiffness and steatosis measurements within TE examination at visit 1 and 2.

Percentage of patients with procedure related adverse events and serious adverse eventsThrough study completion, an average of 24 months

Percentage of patients with procedure related adverse events (adverse events related to TE and liver biopsy) and serious adverse events during all the duration of the study.

Percentage of patients with changes in lifestyle habitsThrough study completion, an average of 24 months

Percentage of patients with changes in lifestyle habits

Trial Locations

Locations (45)

Altstadtpraxis

🇩🇪

Mainz, Germany

Praxis Mombach

🇩🇪

Mainz, Germany

Medicina Di gruppo di montagnana

🇮🇹

Padova, Italy

Vigonza Medica

🇮🇹

Padova, Italy

F. D. Roosevelt Univ. Hospital

🇸🇰

Banská Bystrica, Slovakia

CAP Besos

🇪🇸

Barcelona, Spain

CAP Vila de Gracia

🇪🇸

Barcelona, Spain

CAP Vila Olimpica

🇪🇸

Barcelona, Spain

Hospital Gregorio Marañon

🇪🇸

Madrid, Spain

CAP La Llantia

🇪🇸

Mataró, Spain

James Wigg

🇬🇧

London, United Kingdom

Mild May

🇬🇧

London, United Kingdom

Oakleigh park

🇬🇧

London, United Kingdom

Dubrava Hospital

🇭🇷

Zagreb, Croatia

Poliklinika Croatia

🇭🇷

Zagreb, Croatia

Odense University Hospital

🇩🇰

Odense, Denmark

Centre de santé Municipal Etienne Gatineau-Sailliant de Genevilliers

🇫🇷

Gennevilliers, France

Centre de Recherche Clinique - CRC

🇫🇷

Paris, France

Hospital Avicenne

🇫🇷

Paris, France

Hospital Beaujon

🇫🇷

Paris, France

Homburg Hospital

🇩🇪

Homburg, Germany

Mainz Hospital

🇩🇪

Mainz, Germany

MVZ Dres.Schneider Kaiserslautern

🇩🇪

Rodenbach, Germany

Medical Center Rotterdam

🇳🇱

Rotterdam, Netherlands

Hospital Germans Trias i Pujol

🇪🇸

Badalona, Barcelona, Spain

SEAT

🇪🇸

Martorell, Barcelona, Spain

CAP II El Maresme

🇪🇸

Mataró, Barcelona, Spain

CAP II Santa Coloma de Gramanet

🇪🇸

Santa Coloma De Gramenet, Barcelona, Spain

CAP La Florida

🇪🇸

Santa Perpètua De Mogoda, Barcelona, Spain

CAP Barceloneta

🇪🇸

Barcelona, Spain

Hospital del Mar

🇪🇸

Barcelona, Spain

CAP Bordeta-Magòria

🇪🇸

Barcelona, Spain

CAP Río de Janeiro

🇪🇸

Barcelona, Spain

Oak Lodge Medical Centre

🇬🇧

Edgware, United Kingdom

Royal Free Hospital

🇬🇧

London, United Kingdom

St Andrews Medical Practice

🇬🇧

London, United Kingdom

Nottingham University Hospital

🇬🇧

Nottingham, United Kingdom

King's Mill Hospital

🇬🇧

Sutton In Ashfield, United Kingdom

CAP Ciutat Meridiana

🇪🇸

Barcelona, Spain

CAP Sant Rafael

🇪🇸

Barcelona, Spain

Hospital Universirati Vall d'Hebrón

🇪🇸

Barcelona, Spain

Hospital Clínic de Barcelona

🇪🇸

Barcelona, Spain

CAP Adrià

🇪🇸

Barcelona, Spain

CAP La Marina

🇪🇸

Barcelona, Spain

CAP Numància

🇪🇸

Barcelona, Spain

© Copyright 2025. All Rights Reserved by MedPath